Psychosis, psychedelic substance misuse and head injury: A case report and 23 year follow-up

Sami, Musa; Piggott, Katie; Coysh, Claire; Fialho, Antonio

doi:10.3109/02699052.2015.1046491

Cited by 11 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In total, 15 published case studies met all of the selection criteria, four of which involved psilocybin. [49][50][51][52][53][54][55][56][57][58][59][60][61][62][63] Table 1 summarizes the case content (each case is numbered) and Table 2 summarizes the themes in each case. In terms of themes, of the 15, five case studies appeared to involve some history of mania or hypomania before ingestion of the psychedelic, or a family history of bipolar disorder (Cases 7, 9,11,13,15).…”

Section: Resultsmentioning

confidence: 99%

“…In total, 17 published case studies met all of the selection criteria, five of which involved psilocybin (Barbic et al, 2020;Bickel et al, 2005;Brown et al, 2017;Cohen, 1966;Davies, 1979;Dewhurst, 1980;Dos Santos et al, 2017;Hyde et al, 1978;Lake et al, 1981;Paterson et al, 2015;Perera et al, 1995;Prajapati et al, 2016;Reich and Hepps, 1972;Sami et al, 2015;Szmulewicz et al, 2015;Hendin & Penn, 2021). Table 1 summarizes the case content (each case is numbered) and Table 2 summarizes the themes in each case.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Review of the Research Literature and Published Case Studies

Gard

et al. 2021

Preprint

View full text Add to dashboard Cite

Objective: Given the treatment limitations of depression in bipolar disorder, we evaluated the known risks of using psilocybin (and similar substances) in this population, including a systematic assessment of published case histories, to assess the risk of psilocybin as a treatment of depression in bipolar disorder. Data Sources: A comprehensive search of case studies published through December 31, 2020 was conducted using the following electronic databases: PubMed, Web of Science, and PsychInfo, focusing on classic psychedelics and case studies or case histories. Study Selection: Our search terms resulted in 541 hits, of which 43 were non-duplicates of case studies with individuals having an adverse reaction to a psychedelic substance. Of those, 15 case studies indicated some form of adverse event involving mania or manic like behavior that persisted beyond the acute intoxication of the substance. Data Extraction: Two independent evaluators assessed all possible cases, focusing on manic behavior based on DSM criteria. Two separate evaluators convened to evaluate cases where the case information was unclear. Results: Of the 15 cases, four involved psilocybin, two cases involved individuals with a likely pre-existing diagnosis of bipolar disorder, and three involved individuals without a history of polysubstance abuse or concurrent polysubstance use. Conclusions: We conclude that there is some evidence of risk of activating mania with these substances, but that the risk does not appear to be strong or overwhelming. Instead a careful prospective study, such as an open-label treatment protocol with careful controls, appears warranted in this population.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Review of the Research Literature and Published Case Studies

Gard

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…For some people, negative effects persist for days or weeks, usually depending on how long the transient psychological distress lasts. For some, the risk is greater, precipitating episodes of mania or psychosis (e.g., Sami et al, 2015), and therefore psychotic disorders and borderline personality disorder are potential contraindications, although more research is needed (Cohen, 1985; Rucker et al, 2018). The risks of such negative experiences can be reduced by appropriate dosage, setting, preparation, and support and by not taking multiple doses or combining with other substances.…”

Section: Issues Surrounding Entheogenic and Psychedelic Use In Canadamentioning

confidence: 99%

Entheogens and psychedelics in Canada: Proposal for a new paradigm.

Rochester¹,

Vallely²,

Grof³

et al. 2022

Canadian Psychology / Psychologie canadienne

View full text Add to dashboard Cite

After decades of prohibition, scientific and academic inquiry into the psychedelic sciences has been reignited in the West. Alongside research, clinicians are being permitted to study the effects of psychedelic substances in humans, and the door has been opened to deliver psychedelic-assisted therapies for mental health needs. However, despite excitement for the professional use of psychedelics, there are few, if any, overarching principles regulating such studies and treatment approaches in Canada. To this end, experts in religious studies, psychiatry, clinical psychology, palliative care, anthropology, ethics, and legal studies assembled to assess the developing situation and form recommendations, as an initial step in laying the groundwork for therapeutic, spiritual, and research involvement/activities with psychedelics. This article reviews the historical context of entheogens in indigenous traditions; a current view of the field in Canada; potential risks associated with psychedelic use; recommendations regarding ethical guidelines and education and training for professionals; and criteria for credentialing in psychedelic-assisted therapies. These recommendations comprise the first step in an essential process to connect science, education, varied entheogen and psychedelic practices and our government. The professional recommendations of the committee culminate in advising the creation of a National Advisory Council, adjunct to the Office of Controlled Substances, Health Canada, and a Credentialing Council adjunct to the National Advisory Council. These councils would advise on sustainability and management of entheogenic plants, and education, training, core clinical competencies, ethical codes of conduct, and credentialing for clinicians and practitioners seeking to provide psychedelic-assisted treatments to clients. Public Significance StatementEntheogenic and psychedelic-assisted psychotherapies are poised to become an effective mainstream approach to mental health and wellness in Canada. Practitioner guidelines for ethical practice, training, and credentialing are needed to ensure public safety of this emerging modality.

show abstract

“…Fueron seleccionados inicialmente, tras revisión de título y abstract, un artículo de los hallados en SciELO y 8 artículos de los encontrados en PubMed, tres artículos fueron añadidos tras búsqueda manual por referencias a partir de otras publicaciones. Uno de los artículos de la base de PubMed fue eliminado tras lectura completa del texto debido a que existía un uso concomitante de varias sustancias alucinógenas, por lo que no se ajustaba al objetivo de la presente revisión (12).…”

Section: Criterios De Elecciónunclassified

Episodios psicóticos inducidos por ayahuasca: revisión sistemática a partir de un caso.

2022

View full text Add to dashboard Cite

La ayahuasca pertenece al grupo de alucinógenos de origen vegetal con los que comparte su capacidad de alterar el estado de conciencia y provocar alteraciones perceptivas. Empleada tradicionalmente en forma de brebaje en ritos ceremoniales con el propósito de alcanzar experiencias de contenido espiritual o sanatorio, su uso se ha extendido a lo largo de centurias hasta nuestro actual contexto cultural dentro del cual es empleada por pequeños grupos guiados por fines de crecimiento personal. La experiencia suele durar unas horas y los efectos suelen ser autolimitados. Se describe el caso clínico de una paciente que, tras el consumo experimental de ayahuasca, desarrolla un episodio maníaco con síntomas psicóticos. Se realiza asimismo una búsqueda sistemática de casos publicados de sintomatología psicótica relacionada con el consumo de ayahuasca. A nivel experimental, la relación entre ayahuasca y experiencias psicóticas es poco conocida, si bien se ha determinado un buen perfil de seguridad de la sustancia en administraciones puntuales en sujetos sanos. En el presente estudio, los resultados sugieren que la aparición de episodios psicóticos asociados con consumo de ayahuasca es un fenómeno infrecuente que parece estar relacionado con características de vulnerabilidad tales como historia personal o familiar de trastorno mental grave o el uso concomitante de otros compuestos tóxicos o drogas, especialmente cannabis.

show abstract

Psychosis, psychedelic substance misuse and head injury: A case report and 23 year follow-up

Abstract: It is suggested that psychedelic substance misuse should be investigated as a risk factor for psychotic illness in patients with brain injury, as this case clearly suggests.

Cited by 11 publications

References 16 publications

Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Review of the Research Literature and Published Case Studies

Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Review of the Research Literature and Published Case Studies

Entheogens and psychedelics in Canada: Proposal for a new paradigm.

Episodios psicóticos inducidos por ayahuasca: revisión sistemática a partir de un caso.

Contact Info

Product

Resources

About